From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 50s
Addex Therapeutics Cash Runway at Risk
Addex Therapeutics' cash runway shrinks as it regains GABAB rights and faces funding pressure.
In brief
Addex Therapeutics' cash runway shrinks as it regains GABAB rights and faces funding pressure. Addex Therapeutics has a cash balance of CHF 767,000 and needs funding to advance its GABAB pipeline after regaining rights from Indivior. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Addex Reports Q2 2026 Results
Addex reported Q2 2026 net loss of CHF 1.745 million.
USD 2.8 Million Equity Raise
Addex raised USD 2.8 million through an at-the-market offering.
Returned GABAB Rights
Addex regained GABAB substance-use-disorder rights from Indivior.
Cash Balance Drops
Addex had CHF 767,000 cash at June 30, 2026.
R&D Expense Cuts
Addex reduced H1 2026 R&D expense to CHF 74,000 from CHF 391,000.
Neurosterix Phase 1 Data
Neurosterix expects Phase 1 data for NTX-253 in Q4 2026.
The essence
Addex Therapeutics has a cash balance of CHF 767,000 and needs funding to advance its GABAB pipeline after regaining rights from Indivior.
